286 related articles for article (PubMed ID: 33049091)
1. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond.
Daisy Precilla S; Kuduvalli SS; Thirugnanasambandhar Sivasubramanian A
Cell Biol Int; 2021 Jan; 45(1):18-53. PubMed ID: 33049091
[TBL] [Abstract][Full Text] [Related]
2. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
3. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
4. New molecularly targeted therapies for glioblastoma multiforme.
Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
[TBL] [Abstract][Full Text] [Related]
6. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint: Inspecting the barriers in glioblastoma immunotherapies.
Preddy I; Nandoliya K; Miska J; Ahmed AU
Semin Cancer Biol; 2022 Nov; 86(Pt 3):473-481. PubMed ID: 35150865
[TBL] [Abstract][Full Text] [Related]
9. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
10. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
11. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
12. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
[TBL] [Abstract][Full Text] [Related]
13. Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma.
Mooney J; Bernstock JD; Ilyas A; Ibrahim A; Yamashita D; Markert JM; Nakano I
World Neurosurg; 2019 Sep; 129():90-100. PubMed ID: 31152883
[TBL] [Abstract][Full Text] [Related]
14. Therapy and progression--induced O6-methylguanine-DNA methyltransferase and mismatch repair alterations in recurrent glioblastoma multiforme.
Agarwal S; Suri V; Sharma MC; Sarkar C
Indian J Cancer; 2015; 52(4):568-73. PubMed ID: 26960480
[TBL] [Abstract][Full Text] [Related]
15. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
16. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
[TBL] [Abstract][Full Text] [Related]
18. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
19. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
Bambury RM; Morris PG
Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
